蛋白酪氨酸激酶抑制剂主治慢性骨髓性白血病(CML)的原始细胞危象期、加速期、以及经α干扰素治疗无效的慢性期。
目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。
Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase (PTK).
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂,能阻断酪氨酸蛋白激酶信号传导通路,从而促进肿瘤细胞凋亡。
Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
因此,本研究的目的是调查金雀异黄素,一种蛋白质酪氨酸激酶抑制剂,对有急性或慢性糖尿病炎症小鼠(诱导脲佐菌素)的影响。
Therefore, the aim of this study is to investigate the effects of genistein, a protein tyrosine kinase inhibitor, on acute and chronic inflammation in diabetic mice (induced by streptozotocin).
蛋白酪氨酸激酶抑制剂主治慢性骨髓性白血病(CML)的原始细胞危象期、加速期、以及经α干扰素治疗无效的慢性期。
应用推荐